Exozymes (EXOZ) Research & Development (2023 - 2026)
Exozymes (EXOZ) posted quarterly Research & Development of -$2.5 million for Q4 2025, down 235.84% year-over-year from $1.8 million in Q4 2024, and down 305.36% quarter-over-quarter from $1.2 million in Q3 2025.
Exozymes (EXOZ) Research & Development (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Research & Development for 3 consecutive years, with -$2.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Research & Development fell 235.84% year-over-year to -$2.5 million; the TTM figure through Dec 2025 stood at -$665163.0 (down 131.73% YoY), while the FY2025 annual figure was $95989.0, down 94.86% from the prior year.
- Research & Development declined to -$2.5 million in Q4 2025 per EXOZ's latest filing, from $1.2 million in the prior quarter.
- Across five years, Research & Development topped out at $1.8 million in Q4 2024 and bottomed at -$2.5 million in Q4 2025.
- Historically, Research & Development has averaged $191960.5 across 3 years, with a median of $139615.0 in 2024.
- On a YoY basis, Research & Development climbed as much as 14674.31% in 2025 and fell as far as 235.84% in 2025.
- Exozymes' Research & Development stood at $460385.0 in 2023, then soared by 299.56% to $1.8 million in 2024, then sank by 235.84% to -$2.5 million in 2025.
- Business Quant data shows EXOZ's Research & Development at -$2.5 million in Q4 2025, $1.2 million in Q3 2025, and $41835.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 97.90 Mn |
| 10 | Exozymes | 64.09 Mn | 64.09 Mn | - | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.44 Mn |
| Dec 31, 2025 | -2.50 Mn |
| Sep 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 41,835.00 |
| Mar 31, 2025 | 575,016.00 |
| Dec 31, 2024 | 1.84 Mn |
| Sep 30, 2024 | 15,661.00 |
| Jun 30, 2024 | 237,395.00 |
| Mar 31, 2024 | 3,892.00 |
| Dec 31, 2023 | 460,385.00 |
| Sep 30, 2023 | 27,936.00 |